StemSight

Executive Summary

StemSight is a Finnish pre-clinical biotechnology company pioneering off-the-shelf cell therapies for corneal blindness, a condition affecting millions worldwide with limited treatment options. By combining human pluripotent stem cell-derived cells with functional biomaterials, the company aims to accelerate corneal tissue regeneration and simplify cell delivery, addressing significant unmet medical needs in ocular regenerative medicine. Founded in 2018 and based in Helsinki, StemSight leverages innovative stem cell and biomaterial technologies to develop a scalable, allogeneic therapy that could potentially restore vision in patients with corneal damage or disease. The company's technology platform holds promise for overcoming key challenges in cell therapy, such as immune rejection and complex manufacturing. Currently in the pre-clinical stage, StemSight is focused on advancing its lead candidate toward clinical development. While still early, the company's unique positioning in a niche but high-need area of ophthalmology, combined with its proprietary biomaterial-cell combination, could attract strategic partnerships or funding to support IND-enabling studies. Success in preclinical models and progression to first-in-human trials would be critical value inflection points.

Upcoming Catalysts (preview)

• Q2 2027Announcement of IND/CTA filing for lead candidate40% success
• Q4 2026Strategic partnership with ophthalmology or cell therapy company30% success
• Q3 2026Publication of preclinical proof-of-concept data in peer-reviewed journal60% success